Dulaglutide

Evidence Level: L5 Predicted Indications: 51

Quick Overview

Item Value
Drug Name Dulaglutide
DrugBank ID DB09045
Brand Names (EU) Trulicity
Evidence Level L5
Predicted Indications 51
Top Prediction Score 97.05%

Approved Indication (EMA)

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 a

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 opsismodysplasia 97.05% DL
2 focal stiff limb syndrome 97.05% DL
3 classic stiff person syndrome 97.05% DL
4 thiamine-responsive dysfunction syndrome 96.81% DL
5 diabetes mellitus (disease) 96.57% DL
6 drug-induced localized lipodystrophy 95.62% DL
7 pancreatic agenesis 95.55% DL
8 centrifugal lipodystrophy 95.37% DL
9 pressure-induced localized lipoatrophy 95.29% DL
10 idiopathic localized lipodystrophy 94.99% DL
11 autoimmune oophoritis 69.57% DL
12 cholangiocarcinoma, susceptibility to 65.61% DL
13 hypercarotenemia and vitamin A deficiency, autosomal recessive 64.93% DL
14 hemoglobin C-beta-thalassemia syndrome 64.30% DL
15 type 1 diabetes mellitus 63.72% DL
16 atrial flutter (disease) 63.47% DL
17 pancreas, dorsal, agenesis of 61.12% DL
18 familial chronic myelocytic leukemia-like syndrome 60.46% DL
19 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 59.90% DL
20 mitral valve prolapse, myxomatous 59.70% DL

Showing top 20 of 51 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.